Immutep says EFTISARC-NEO Phase II ePoster on efti HRQoL in soft tissue sarcoma accepted for ESMO 2026
IMMP•ESMO 2026 ePoster accepted
Immutep said an ESMO Congress 2026 ePoster from the Phase II EFTISARC-NEO trial of eftilagimod alfa in soft tissue sarcoma has been accepted.
Results have not been presented yet; the abstract is scheduled to post online Oct. 19, 2026, ahead of the Oct. 23-27 meeting.
Focus on patient-reported quality of life
The readout focuses on patient-reported quality of life during neoadjuvant treatment combining eftilagimod alfa with pembrolizumab and radiotherapy.
The update signals continued clinical momentum for efti, with investor attention likely on tolerability and treatment experience alongside efficacy.
